KHKimberley Iris Hemelrijk

Kimberley Iris Hemelrijk

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Kimberley Iris Hemelrijk has a total of 94 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Permanent Pacemaker Implantation in Patients Undergoing Transcatheter Aortic Valve Implantation: From Incidence to Outcomes

    by Gijs M. Broeze, Kimberley I. Hemelrijk, Pilar Jimenez-Quevedo, Didier Tchétché, Fabio S. de Brito, Marco Barbanti, Ran Kornowski, Azeem Latib, Augusto D’ONofrio, Flavio Ribichini, et al.

  • Open Access

    Surgical Versus Transcatheter Aortic Valve Replacement in Bicuspid Aortic Stenosis: 1‐Year Clinical Outcomes in Patients Aged 65 Years and Older

    by Kimberley Iris Hemelrijk, Matias R Mon Noboa, Gabriela Tirado‐Conte, Toon Winkelman, Lluis Asmarats, Elena Rosello‐Diez, Daniel Perez‐Camargo, Yusuke Kobari, Thibaut Guitteny, Angela McInerney, et al.

    Background: Transcatheter aortic valve replacement (TAVR) has shown noninferiority to surgical aortic valve replacement (SAVR). However, patients with bicuspid aortic stenosis are often excluded from these studies. More insights between these procedures in this population is crucial for treatment selection. Methods: In this multicenter observational study, patients with bicuspid aortic stenosis undergoing TAVR or SAVR were analyzed using propensity score matching. The primary outcome was a composite of all‐cause mortality, stroke, rehospitalization, or valve dysfunction at 1 year. Results: A total of 997 patients with bicuspid aortic stenosis underwent TAVR or SAVR. In the matched cohort of 256 pairs, the median age was 75.0 years (interquartile range, 71.0–78.0), 234 (44.9%) were women, and the median EuroScore II was 1.83% (interquartile range, 1.34–2.86). One‐year cumulative incidence of the primary outcome was 15.0% in TAVR compared with 12.0% in SAVR (hazard ratio [HR], 1.35 [95% CI, 0.83–2.19], P =0.23). Mortality (4.3% versus 5.0%, P =0.72) and rehospitalization (4.8% versus 6.4%, P =0.45) were similar between groups. Although rates of valve dysfunction (2.9% versus 0.5%, P =0.06) and stroke (5.3% versus 2.3%, P =0.10) were numerically lower in the surgical group at 1 year, both the risk of stroke (subdistribution HR, 3.01, P =0.02) and valve dysfunction (subdistribution HR, 4.16, P =0.03) were significantly higher in the TAVR group at 2 years. Conclusions: TAVR in patients with bicuspid aortic stenosis showed a similar 1‐year primary outcome rate compared with SAVR, though TAVR exhibited higher rates of valve dysfunction and stroke. These findings underscore the need for randomized trials to define the optimal treatment strategy for this population.


  • Open Access

    Pre‐Existing and New‐Onset Atrial Fibrillation in Patients Undergoing Transcatheter Aortic Valve Implantation

    by Kimberley I. Hemelrijk, Astrid C. van Nieuwkerk, Philomene J. Vojacek, Livia Gheorge, Didier Tchétché, Fabio S. de Brito, Marco Barbanti, Ran Kornowski, Azeem Latib, Augusto D'ONofrio, et al.

    Background: Atrial fibrillation (AF) is a frequent comorbidity in patients with severe aortic valve stenosis undergoing transcatheter aortic valve implantation (TAVI). In addition, new‐onset AF can occur after TAVI. However, data on how AF affects outcomes in patients undergoing TAVI remain conflicting. Aims: To assess clinical outcomes in patients with severe aortic valve stenosis with AF who undergo TAVI in a large real‐world global cohort. Methods: The CENTER2‐study includes 25,771 patients that underwent TAVI between 2007 and 2022. The database consists of patient‐level pooled data from 10 clinical studies. Objectives were rates of new‐onset AF ≤ 30 days, and differences in mortality and stroke according to AF status. Results: A total of 23,320 patients were included in the current analysis (56.1% female; mean age 81.5 ± 6.7 years). Pre‐existing AF was present in 28.2% ( n = 6579) of patients. Mortality rates after TAVI were higher in patients with pre‐existing AF (19.0% vs. 14.2%, adjusted HR: 1.39, 95% CI: 1.26–1.53, p < 0.001). Strokes at Day 3–30 after TAVI were more frequent in patients with pre‐existing AF (1.6% vs. 1.1%, p = 0.004). New‐onset AF occurred in 6.2% ( n = 681) of patients without pre‐existing AF. Mortality rates after TAVI were higher in patients with new‐onset AF (adjusted HR 1.75, 95% CI 1.24–2.49, p = 0.002). One‐year stroke was more frequently observed in patients with new‐onset AF after exclusion of acute periprocedural stroke (6.1% vs. 3.4%, p = 0.04). Major bleeding was also more frequent in patients with new‐onset AF (12.0% vs. 6.7%, p < 0.001). Conclusions: Patients with pre‐existing or new‐onset AF had higher mortality compared with patients without AF undergoing transfemoral TAVI. After the acute postprocedural period, 1‐year stroke rates were higher in patients with new‐onset AF. Trial Registration: ClinicalTrials.gov . Unique identifier NCT03588247.

  • Open Access

    Cerebral blood flow and cognitive functioning in patients undergoing transcatheter aortic valve implantation

    by Astrid C. van Nieuwkerk, Kimberley I. Hemelrijk, Hugo M. Aarts, Anna E. Leeuwis, Charles B.L.M. Majoie, Mat J.A.P. Daemen, Esther E. Bron, Justine E.F. Moonen, Alexandra de Sitter, Berto J. Bouma, et al.


  • Open Access

    Cerebrovascular Events in Patients Undergoing Transfemoral Transcatheter Aortic Valve Implantation: A Pooled Patient‐Level Study

    by Astrid C. van Nieuwkerk, Hugo M. Aarts, Kimberley I. Hemelrijk, Cristobal Urbano Carrillo, Didier Tchétché, Fabio S. de Brito, Marco Barbanti, Ran Kornowski, Azeem Latib, Augusto D'ONofrio, et al.

    Background: Cerebrovascular events remain one of the most devastating complications of transcatheter aortic valve implantation (TAVI). Data from real‐world contemporary cohorts on longitudinal trends and outcomes remain limited. The aim of this study was to assess incidence, temporal trends, predictors, and outcomes of cerebrovascular events following transfemoral TAVI. Methods and Results: The CENTER2 (Cerebrovascular Events in Patients Undergoing Transcatheter Aortic Valve Implantation With Balloon‐Expandable Valves Versus Self‐Expandable Valves 2) study includes patients undergoing TAVI between 2007 and 2022. The database contains pooled patient‐level data from 10 clinical studies. A total of 24 305 patients underwent transfemoral TAVI (mean age 81.5±6.7 years, 56% women, median Society of Thoracic Surgeon Predicted Risk of Mortality 4.9% [3.1%–8.5%]). Of these patients, 2.2% (n=534) experienced stroke in the first 30 days after TAVI, and 40 (0.4%) had a transient ischemic attack. Stroke rates remained stable during the treatment period (2007–2010: 2.1%, 2011–2014: 2.5%, 2015–2018: 2.1%, 2019–2022: 2.1%; P trend =0.28). Moreover, 30‐day cerebrovascular event rates were similar across Society of Thoracic Surgeon Predicted Risk of Mortality risk categories: 2.1% in low‐risk, 2.6% in intermediate‐risk, and 2.5% in high‐risk patients ( P =0.21). Mortality was higher in patients with 30‐day stroke than without at 30 days (20.3% versus 4.7%; odds ratio, 5.1 [95% CI, 4.1–6.5]; P P P trend =0.32). At 1 year, 7.0% of patients undergoing TAVI had a stroke. Conclusions: In 24 305 patients who underwent transfemoral TAVI, 30‐day cerebrovascular event incidence remained ≈ 2.2% between 2007 and 2022. Thirty‐day stroke rates were similar throughout Society of Thoracic Surgeon Predicted Risk of Mortality risk categories. Mortality rates after stroke remain high. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03588247.


  • Open Access

    A Travel Through Time

    by Kimberley Iris Hemelrijk, Daniel Faria, Pablo Salinas, Javier Escaned